IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
2024年9月3日 - 9:00PM
via IBN – IBN, a multifaceted communications organization engaged
in connecting public companies to the investment community, is
pleased to announce the release of the latest episode of The
BioMedWire Podcast as part of its sustained effort to provide
specialized content distribution via widespread syndication
channels.
The BioMedWire Podcast features fast-paced interviews with
experts guiding the next wave of pharmaceutical and biotech
innovation. The latest episode features John Climaco, CEO of CNS
Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company
specializing in the development of novel treatments for primary and
metastatic cancers in the brain and central nervous system.
To begin the interview, Climaco discussed CNS Pharmaceuticals’
business model, including the company’s recent announcement of an
exclusive in-license agreement to expand its development
pipeline.
“We are an oncology drug development company. Specifically, our
space is neuro-oncology – cancers of the brain and the central
nervous system. Traditionally, these are some of the most difficult
and deadly cancers,” he said. “They are very challenging to treat,
because they lie beyond the blood-brain barrier, which is this very
specialized network of cells that protects the most important organ
in the body. It's very hard to get drugs and treatments to the
brain when you have tumors growing in it, so that is really what we
specialize in.”
“We have a very exciting compound called Berubicin. It's a
first-in-class drug that penetrates the blood-brain barrier and
treats brain cancer. This is in a late stage, designed to be
pivotal trial, with over 250 patients in the United States and
Europe currently enrolled. It'll be reading top-line data in the
first half of next year, so we're very excited about that. We've
been working on Berubicin since the company's inception back in
2017.”
“Our recent news is equally exciting. After many years of
searching and diligence and evaluating over 200 different compounds
for potential in-license, we settled on an amazing drug called
TPI-287, which is a novel abeotaxane of the taxane family. This is
also a unique blood-brain barrier penetrant drug that was
specifically designed to treat these very difficult brain cancers,
such as glioblastoma. This drug has already been used in 350
patients in a series of phase one studies. We are just getting
started on planning what will be another designed to be pivotal
study for this very exciting drug.”
Join IBN’s Carmel Fisher and John Climaco, CEO of CNS
Pharmaceuticals Inc., to learn more about what sets Berubicin, as
well as the company’s new TPI-287 candidate, apart from anything
else in development for glioblastoma.
To hear the episode and subscribe for future podcasts,
visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers, and the growing IBN Podcast
Series. For more than 18 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and
connect with the Company on X, Facebook and LinkedIn.
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 18+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
CNS Pharmaceuticals (NASDAQ:CNSP)
過去 株価チャート
から 11 2024 まで 12 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
過去 株価チャート
から 12 2023 まで 12 2024